ReviewNature reviews. Immunology2012
Recent progress in mucosal vaccine development: potential and limitations.
Review in Nature reviews. Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 423 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
423 citing papers in PubMed, 3 syntheses or guidelines pooled it, 777 citations in OpenAlex.
- Preclinical Evaluation of Bacterial Lysates in Murine Disease Models: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026Pooled it
- Gut distress and interventionFrontiers in public health · 2023Pooled it
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- [Molecular mechanisms of chronic gastric mucosal inflammation induced byZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- GnRH-Based Immunocastration Vaccines: Comparative Analysis and Role in Boar Taint Reduction.Vaccines · 2026Review
- A yeast-based oral vaccine platform reveals antigen-dependent protection against Eimeria tenella.Poultry science · 2026Article
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.PLoS pathogens · 2026Article
- Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.Vaccines · 2026Article
- Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.Science advances · 2026Article
- Extracellular Vesicles ofJournal of extracellular biology · 2026Article
- Aerosol Inhalation of a Recombinant H7N9 Hemagglutinin Antigen Elicits Systemic and Mucosal Immune Responses in Mice.Viruses · 2026Article
- Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies.Biomedicines · 2026Review
- Alcaligenes lipid A as a sublingual adjuvant to augment protective immune responses in the respiratory and gastrointestinal tracts.International immunology · 2026Article
- Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses.EBioMedicine · 2026Article
- Article
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Liposomal simvastatin potentiates intranasal H1N1 influenza subunit vaccineActa pharmaceutica Sinica. B · 2026Article
- Review
- Review
363 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and great expectations for new mucosal vaccines lie ahead. Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.